The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and toxicity of KIT targeted therapy in elderly patients with melanoma.
 
Ronen Stoff
Honoraria - Bristol-Myers Squibb Israel; Medison; Merck Serono; Merck Sharp & Dohme; Novartis; Roche Israel
Consulting or Advisory Role - Pangaea Biotech
 
Svetomir Markovic
Stock and Other Ownership Interests - Sorrento Therapeutics
Consulting or Advisory Role - Sorrento Therapeutics
Research Funding - Bristol-Myers Squibb; Nektar; Sorrento Therapeutics
Patents, Royalties, Other Intellectual Property - Nanoparticles (patents); Nanoparticles - immunoconjugates
 
Robert R. McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Yiyi Yan
No Relationships to Disclose
 
Winston Tan
Honoraria - Medscape; Onclive
 
Mahesh Seetharam
Honoraria - AADi; Daiichi Sankyo; Deciphera; Horizon CME
Travel, Accommodations, Expenses - Horizon CME
 
Matthew Stephen Block
Research Funding - Alkermes; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Immune Design (Inst); Marker, Inc. (Inst); Merck (Inst); nference; Pharmacyclics (Inst); Regeneron; Sorrento Therapeutics (Inst); TILT Biotherapeutics; Transgene (Inst); Viewpoint Molecular Targeting
(OPTIONAL) Uncompensated Relationships - Sorrento Therapeutics; TILT Biotherapeutics; Viewpoint Molecular Targeting